Children’s Hospital Los Angelesiffadmin2020-04-16T15:45:49-04:00
CHILDREN’S HOSPITAL LOS ANGELES
Dr. Stefan Bluml of Children’s Hospital Los Angeles has determined elevated citrate levels can predict future risk for disease progression for certain types of brain tumors. He is currently exploring mechanisms that might cause the increased levels of citrate. His long-term goal is to be able to exploit our improved understanding of tumor metabolism to design more effective therapies.
To date, Ian’s Friends Foundation has committed millions of dollars toward pediatric brain tumor research at the cutting-edge research institutions listed below.
Long-term goal is to improve understanding of tumor metabolism to design more effective therapies.
New biorepository will provide the technology to grow and store cancer cells for use in brain tumor research.
Together, these Atlanta institutions pioneer the use of nanotechnology to gauge tumor size, stop tumor growth, and shrink tumors.
Research focused on uncovering the mechanisms by which gene fusions contribute to tumor formation in pediatric low grade gliomas.
Objective is to determine if an electrical stimulations regimen can arrest the division of dividing brain tumor cells.
Working to find biomarkers for brain tumors to make the diagnosis of tumor types easier, track their growth or even, no recurrence.
Research establishing the feasibility of using interstitial infusion for treating pediatric brain stem gliomas. FDA approved clinical trial underway.
Research focused on proteins which are active in pediatric low-grade gliomas. From this research, NYU hopes to better select molecular targeted drugs directed at these pathways.
Research focused on using new brain imaging techniques to improve diagnosis, prognosis and treatment of pediatric brain tumors.
Partnership between a physician and research scientist is examining innovative drug delivery methods for children with brain tumors.
This groundbreaking project could be the first step for the development of a variety of attractive modalities targeting therapeutic approaches beyond immunotherapy.
Discovery regarding cancer cells' ability to hijack the brain's nerves could lead to new treatment avenues for aggressive brain tumors.
Developing a strategy to ensure rapid translation of new drug candidates into clinical trials of medulloblastomas is a collaborative effort.
University of Michigan Researchers aim to treat Pediatric Brain Tumors through the combination of Gene and Immune Therapy.
Researchers at Johns Hopkins All Children’s and Johns Hopkins University hypothesize that a group of lncRNAs, including lncRNA HLX2-7, are key molecular signatures (biomarkers) and therapeutic targets for Group III medulloblastoma in children.
Scientists work to establish a new system for targeting oncogenic mutations in pediatric brain tumors.